Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 13/20 | 0.40 |
| ▸ | SMARCA2 | P51531 | 10/20 | 0.40 |
| ▸ | SMARCA4 | P51532 | 10/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 6/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23607105 | 0.91 | PBRM1 (0.40) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL25131935 | 0.89 | GABRA3 (0.43) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL23607096 | 0.86 | KDM4E (0.39) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL23607100 | 0.86 | KDM4E (0.39) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL24461557 | 0.85 | PBRM1 (0.39) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL25653313 | 0.85 | CHRNA7 (0.49) | PBRM1SMARCA2SMARCA4NR1I2ALDH1A1 | |
| SCHEMBL25653156 | 0.83 | ALDH1A1 (0.38) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL24461314 | 0.81 | BAZ2B (0.55) | PBRM1SMARCA2SMARCA4BRD4MAPT | |
| SCHEMBL30552396 | 0.81 | BAZ2B (0.41) | PBRM1SMARCA2SMARCA4NR1I2MAPT | |
| SCHEMBL27064491 | 0.81 | SMARCA2 (0.38) | PBRM1SMARCA2SMARCA4NR1I2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230103415-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| WO-2021133917-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103415-A1 | SMARCA INHIBITORS AND USES THEREOF | SMARCC1, SMARCE1, SMARCA1 | PBRM1 139/4885SMARCA2 6/4885SMARCA4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.